JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Amicus Therapeutics (NASDAQ:FOLD) Stock

Amicus Therapeutics (NASDAQ:FOLD - Free Report) had its target price increased by JPMorgan Chase & Co. from $16.00 to $17.00 in a research report report published on Tuesday morning,Benzinga reports. The firm currently has an overweight rating on the biopharmaceutical company's stock.

FOLD has been the subject of several other reports. StockNews.com lowered Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday. Needham & Company LLC reaffirmed a "hold" rating on shares of Amicus Therapeutics in a research report on Thursday, November 7th. Morgan Stanley reduced their target price on shares of Amicus Therapeutics from $19.00 to $18.00 and set an "overweight" rating for the company in a report on Friday, October 11th. Jefferies Financial Group assumed coverage on shares of Amicus Therapeutics in a research report on Friday, September 6th. They set a "buy" rating and a $18.00 price objective on the stock. Finally, Cantor Fitzgerald raised their price target on Amicus Therapeutics from $20.00 to $21.00 and gave the company an "overweight" rating in a report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $17.63.

Amicus Therapeutics Stock Down 1.9 %

FOLD stock traded down $0.20 during midday trading on Tuesday, hitting $10.49. The company's stock had a trading volume of 2,683,396 shares, compared to its average volume of 2,728,473. The firm's 50-day moving average is $11.11 and its 200-day moving average is $10.61. The company has a current ratio of 3.15, a quick ratio of 2.26 and a debt-to-equity ratio of 2.18. Amicus Therapeutics has a 12 month low of $9.02 and a 12 month high of $14.57. The company has a market cap of $3.13 billion, a PE ratio of -31.47 and a beta of 0.68.

Insider Buying and Selling

In related news, CEO Bradley L. Campbell sold 7,500 shares of the firm's stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $10.60, for a total value of $79,500.00. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at $9,398,532.40. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Bradley L. Campbell sold 7,901 shares of the business's stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $12.50, for a total transaction of $98,762.50. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares of the company's stock, valued at approximately $11,083,175. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Bradley L. Campbell sold 7,500 shares of the firm's stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $10.60, for a total transaction of $79,500.00. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at $9,398,532.40. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 30,401 shares of company stock worth $352,038. Insiders own 2.20% of the company's stock.

Institutional Investors Weigh In On Amicus Therapeutics

Hedge funds have recently made changes to their positions in the stock. Janus Henderson Group PLC grew its position in shares of Amicus Therapeutics by 20.1% in the 1st quarter. Janus Henderson Group PLC now owns 13,814,514 shares of the biopharmaceutical company's stock worth $162,713,000 after buying an additional 2,307,385 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund grew its holdings in shares of Amicus Therapeutics by 583.4% during the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 2,176,600 shares of the biopharmaceutical company's stock valued at $25,640,000 after buying an additional 1,858,100 shares during the last quarter. Millennium Management LLC raised its stake in Amicus Therapeutics by 1,758.9% in the 2nd quarter. Millennium Management LLC now owns 1,894,176 shares of the biopharmaceutical company's stock worth $18,790,000 after acquiring an additional 1,792,277 shares during the last quarter. William Blair Investment Management LLC grew its stake in Amicus Therapeutics by 12.8% during the 2nd quarter. William Blair Investment Management LLC now owns 13,003,363 shares of the biopharmaceutical company's stock valued at $128,993,000 after purchasing an additional 1,477,084 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its holdings in shares of Amicus Therapeutics by 141.1% in the third quarter. Assenagon Asset Management S.A. now owns 2,037,896 shares of the biopharmaceutical company's stock valued at $21,765,000 after purchasing an additional 1,192,489 shares during the period.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.